| DB ID | MyCo_2051 |
| Title | Comparison of the results of intradermal test reactivity and serum allergen-specific IgE measurement for Malassezia pachydermatis in atopic dogs |
| Year | 2014 |
| PMID | 25130045 |
| Fungal Diseases involved | Atopic dermatitis |
| Associated Medical Condition | None |
| Genus | Malassezia |
| Species | pachydermatis |
| Organism | Malassezia pachydermatis |
| Ethical Statement | Serum samples were obtained from privately owned dogs presented to our facility’s dermatology clinic between 2006 and 2013, in accordance with standards and approval from the School of Veterinary Medicine Animal Care and Use Committee. |
| Site of Infection | Skin |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Animal |
| Host Common name | Dog |
| Host Scientific name | Canis lupus familiaris |
| Biomarker Name | anti-Malassezia IgE |
| Biomarker Full Name | anti-Malassezia Immunoglobulin E |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Animals – Eighty-four dogs with a clinical diagnosis of AD. Serum samples were obtained from privately owned dogs presented to our facility’s dermatology clinic between 2006 and 2013, in accordance with standards and approval from the School of Veterinary Medicine Animal Care and Use Committee. Samples had been stored continuously at _80°C. Sera (n = 84) were selected from dogs meeting the following criteria: (i) clinical diagnosis of AD according to the accepted criteria in use at the time of presentation (these varied according to the year of diagnosis);25,26 (ii) exclusion of other pruritic dermatoses, such as ectoparastic infestation, flea allergy dermatitis or dermatophytosis, using standard diagnostic techniques and lack of response to external parasite control; (iii) completion of a strict dietary restriction trial using a commercial novel protein or hydrolysed diet, as appropriate to the dog at the time; and (iv) completion of a multi-allergen IDT with concurrent (i.e. same day) serum sample obtained for serology testing. The minimal drug withdrawal time prior to IDT was as follows: 7 days for antihistamines; 14 days for oral glucocorticoids; and 28 days for injectable glucocorticoids. |
| Cohort No. | 84 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.77 |
| Specificity | 0.89 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The yeast Malassezia pachydermatis is a constituent of the normal skin flora of healthy dogs. It is typically present in low numbers, but can function as an opportunistic pathogen as a result of changes in the natural defenses of the epidermis. Conditions that may predispose a dog to M. pachydermatis overgrowth include, but are not limited to, atopic dermatitis (AD) and seborrhoea. In addition to acting as an opportunistic pathogen, M. pachydermatis can also act as a trigger for clinical signs in some dogs with AD if hypersensitivity to yeast allergens develops. Both immediate-type and delayed-type hypersensitivity reactions to this yeast have been well documented in some dogs with AD. It is important for clinicians to understand that clinical signs of Malassezia dermatitis, the finding of yeast organisms on cytology and demonstration of potential Malassezia hypersensitivity, using serological or intradermal testing methods, are three separate (but often related) concepts. These three elements may or may not coexist in a given case. Likewise, it is recognized in humas that Malassezia species can trigger and exacerbate the clinical signs of head and neck dermatitis, a form of AD. Treatment with antifungal agents results in improvement in symptoms of human patients with AD. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, FceRIa receptor reagent Intradermal testing |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
